Search the Newsreel

PC Connection (CNXN) CFO sells 20,000 shares in July 31 trades

PC Connection (CNXN) CFO Thomas C. Baker sold a total of 20,000 shares of common stock on July 31, 2026, across two separate open-market transactions. The shares were sold at weighted-average prices of $83.17 and $83.89 per share, totaling approximately $1.66 million. Following these …

World Kinect Corp (NYSE: WKC) insider plans sale of 10,000 shares after RSU vesting

World Kinect Corp insider Michael Kasbar has filed a notice to sell 10,000 shares of common stock, valued at $394,146.64, on or after August 3, 2026. These shares are from restricted stock units that vested on March 14, 2025. The filing also notes several …

Fennec Pharmaceuticals (FENC) CCO receives 168 vested shares

Fennec Pharmaceuticals' Chief Commercial Officer, Terry L. Evans, acquired 168 Common Shares on July 31, 2026, through the vesting of restricted shares originally awarded in March 2025. This transaction increases his direct holdings to 21,351 Common Shares. The shares were acquired at a price …

Fennec Pharmaceuticals (FENC) CEO gets 1,159-share award

Fennec Pharmaceuticals CEO Jeffrey S. Hackman received an award of 1,159 common shares on July 31, 2026, stemming from the release of restrictions on

Fennec Pharmaceuticals (FENC) CMO gains 168 shares as award vests

Fennec Pharmaceuticals' Chief Medical Officer, Pierre Sargis Sayad, acquired 168 common shares on July 31, 2026, as restrictions were released on an award from March 28, 2025. This transaction, valued at $0.00 per share, increased his direct ownership to 21,351 common shares. The acquisition …

Top Healthcare Analyst: A $400 Billion AstraZeneca-Bristol Myers Deal Could “Cut Costs in a Big Way”

Quick Read BMY's existing $2B cost-savings program and discounted forward P/E of ~10 make it an attractive AZN acquisition target, Holz argues. Eli Lilly's $1 trillion market cap dwarfs all pharma rivals, pushing companies like Merck to pursue deals ahead of looming patent cliffs. …

AstraZeneca Investors See Little Logic in Bristol Tie-Up

AstraZeneca Plc investors had a clear message for the UK drugmaker on Monday: they don't like the idea of a $400 billion merger with Bristol-Myers Squibb Co. Bloomberg Intelligence's Director of Research, Sam Fazeli joins to discuss. View Comments

Stocks mixed as AstraZeneca merger talk dents FTSE 100

The FTSE 100 underperformed European peers on Monday as heavy falls in AstraZeneca outweighed more optimistic noises in the Middle East. The FTSE 100 index closed down 10.35 points, 0.1%, at 10,857.70. The FTSE 250 ended up 249.75 points, 1.0%, at 24,224.77, while the …

AstraZeneca shares slump after $400bn BMS merger rumours

Shares in AstraZeneca dropped by nearly 3% at market open after a report that the drugmaker is in talks with oncology rival Bristol Myers Squibb (BMS) regarding a mega-merger deal. According to the Financial Times (FT), which first reported the discussions, a tie-up would …

AstraZeneca Nosedives On A Rumored Megamerger; Is $160 Billion Enough?

AstraZeneca stock took a nosedive Monday amid reports it's mulling a megamerger with Bristol Myers Squibb. Continue Reading

Bristol-Myers Squibb and AstraZeneca said to discuss megamerger - can it happen?

Investing.com - AstraZeneca are trading roughly 9% lower on Monday after the Financial Times first reported, followed by Reuters and Bloomberg, that the British drugmaker held preliminary discussions with Bristol Myers Squibb about a combination that would create a nearly $400 billion pharmaceutical giant. …

Top Midday Stories: Amazon Market Cap Hits $3 Trillion; AstraZeneca, Bristol Myers Squibb Reportedly Discuss $400 Billion Combination

All three major US stock indexes were up in late-morning trading Monday after President Donald Trump PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already …

Astra Buying Bristol Makes No Sense, Fazeli Says

AstraZeneca shares plunged Monday on news that the drugmaker was exploring an acquisition of Bristol Meyers Squibb. A deal would create one of the world's biggest drugmakers. Sam Fazeli of Bloomberg Intelligence says a takeover would make no sense. View Comments

European Stocks Close Mostly Higher in Monday Trading; AstraZeneca Reportedly in Merger Talks With Bristol Myers

European stock markets closed mostly higher in Monday trading as the Stoxx Europe gained 0.4%, Germa PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already …

Bristol Myers Squibb Stock Jumps on Reported Merger Talks With AstraZeneca

AstraZeneca completed a direct listing on the New York Stock Exchange back in February, after delisting its American Depositary Receipts from the Nasdaq Credit: Michael Nagle / Bloomberg via Getty Images Key Takeaways Bristol Myers Squibb shares rose Monday following reports of merger talks …

AstraZeneca Stock Nosedives On Mega-Merger Rumor

AstraZeneca stock took a nosedive Monday amid reports it's mulling a mega-merger with Bristol Myers Squibb. Continue Reading

AIM ImmunoTech Ahead of Schedule on ‘Last Dose’ DURIPANC Critical Clinical Inflection Point

AIM ImmunoTech Inc. Milestone Advances Ampligen® Toward Key Clinical Benefit Readout in December 2026 and Overall Survival Analysis in Mid-2027 OCALA, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced that the final subject …

AstraZeneca slides Monday, underperforms market

AstraZeneca PLC (AZN) shares fell by 8.96% to £115.00 on Monday, underperforming the broader market as the FTSE 100 Index also saw a slight decline. This drop left AstraZeneca's stock 26.90% below its 52-week high achieved in February.

AstraZeneca Weighs a Deal Its CEO Said It Didn't Need

This article first appeared on GuruFocus. AstraZeneca (NYSE:AZN), the UK drugmaker and the country's second most valuable listed company, fell 6.27% in London after news that it has held talks with Bristol Myers Squibb (NYSE:BMY) about a combination valued near $400 billion, according to …

Bristol Myers Squibb Stock Soars on Report of $400 Billion Merger Talks With AstraZeneca

The merger would be one of the biggest pharma deals ever. AstraZeneca’s market capitalization stood at $264 billion as of Friday’s close, while Bristol Myers Squibb had a total valuation of $133 billion. Continue Reading

AstraZeneca shares slide 7% after reports of Bristol Myers talks

Drew Angerer/Getty Images News AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]) and Bristol Myers Squibb (BMY [https://seekingalpha.com/symbol/BMY]) have held preliminary discussions about a potential combination that would create one of the world's largest pharmaceutical companies, according to a report by the Financial Times. For investors, a deal would …

Bristol Myers Squibb (BMY) In Early Merger Talks With AstraZeneca

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Reports indicate AstraZeneca and Bristol-Myers Squibb are in early talks regarding a potential merger. …

AstraZeneca in talks over £300bn mega-merger with US rival – reports

AstraZeneca has held talks with US rival Bristol Myers Squibb over a merger which could create a drugs giant worth more than £300 billion, according to reports. The two pharmaceutical firms have held discussions over a potential tie-up in recent months, the Financial Times …

AstraZeneca shares slide 7% on talks to buy Bristol Myers Squibb

AstraZeneca's shares fell by 7% on news of potential talks to acquire US rival Bristol Myers Squibb, a deal that could create a pharmaceutical giant worth nearly $400 billion. The acquisition would significantly expand AstraZeneca's presence in the US and mark a strategic shift …

Waste Connections, Inc. (NYSE:WCN) Given Average Rating of "Moderate Buy" by Brokerages

Rathbones Group PLC Reduces Stock Holdings in Waste Connections, Inc. $WCN

AstraZeneca, Bristol Myers Squibb Explore US$400 Billion Merger

The merger would be one of the biggest pharma deals ever. AstraZeneca’s market capitalization stood at $264 billion as of Friday’s close, while Bristol Myers Squibb had a total valuation of $133 billion. Continue Reading

AstraZeneca, Bristol Myers held merger talks, Financial Times reports (AZN:NYSE)

Drew Angerer/Getty Images News AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]) and Bristol Myers Squibb (BMY [https://seekingalpha.com/symbol/BMY]) have held preliminary discussions about a potential combination that would create one of the world's largest pharmaceutical companies, according to a report by the Financial Times. For investors, a deal would …

AstraZeneca And Bristol Myers Reportedly In Talks On $400 Bln Deal

(RTTNews) - AstraZeneca Plc (AZN) and Bristol Myers Squibb (BMY) are in talks over a $400 billion deal to combine the companies, Financial Times reported. Neither company has disclosed any details of the merger, and deal closure timelines are unclear. Both AstraZeneca and Bristol …

ETFs Investing in World Kinect Corporation Stocks

This article lists Exchange Traded Funds (ETFs) that hold World Kinect Corporation (WFK) stocks, categorized by market value. It provides details for each ETF, including its issuer, management style, focus, expense ratio, assets under management (AUM), and price performance. The funds generally focus on …

Pc Connection Posts Record Earnings Amid Backlog Surge

AstraZeneca and Bristol-Myers Squibb in talks over potential merger - Report

Investing.com -- AstraZeneca PLC (NYSE:AZN) and Bristol-Myers Squibb Company (NYSE:BMY) have held talks in recent months about a deal that would combine the companies into one, according to a Financial Times report. A combined entity would carry a value of nearly $400 billion, which …

AstraZeneca plots £300bn tie-up with US rival

AstraZeneca is plotting a $400bn (£300bn) merger with US rival Bristol Myers Squibb in a deal likely to raise fresh questions over the company's ties to the UK. Britain's second-most valuable company has held talks with Bristol Myers Squibb in recent months about a …

AstraZeneca, Bristol Myers Squibb Reportedly in Talks for $400 Billion Merger

AstraZeneca and Bristol Myers Squibb are reportedly in discussions for a merger that could create a pharmaceutical giant valued at approximately $400 billion. The talks have been ongoing for several months and, if successful, would make AstraZeneca the world’s fourth-largest drugmaker by market capitalization. …

AstraZeneca holds talks with Bristol Myers Squibb on $400 billion megadeal, FT reports

AstraZeneca has reportedly held talks with Bristol Myers Squibb regarding a potential merger that could create a pharmaceutical giant valued at nearly $400 billion. The Financial Times reported on Sunday that discussions have occurred in recent months, though a deal could still be delayed …

AstraZeneca, Bristol Myers held merger talks, Financial Times reports

Drew Angerer/Getty Images News AstraZeneca (AZN [https://seekingalpha.com/symbol/AZN]) and Bristol Myers Squibb (BMY [https://seekingalpha.com/symbol/BMY]) have held preliminary discussions about a potential combination that would create one of the world's largest pharmaceutical companies, according to a report by the Financial Times. For investors, a deal would …